Dossier assessment
Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
03-04-2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A24-107
- Commission
- Commission awarded on 15.10.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-107_en
Connected Projects
-
Addendum
Delgocitinib (moderate to severe chronic hand eczema) – Addendum to Project A24-107
Status: Commission completed